<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952857</url>
  </required_header>
  <id_info>
    <org_study_id>INT/2020/001068</org_study_id>
    <nct_id>NCT04952857</nct_id>
  </id_info>
  <brief_title>Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease</brief_title>
  <acronym>SHADE-S</acronym>
  <official_title>Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 caused by SARS-CoV-2 virus has affected the lives of millions of individuals&#xD;
      globally and also severely strained the medical community. Pre-symptomatic and asymptomatic&#xD;
      SARS-CoV-2 positive individuals far outnumber the symptomatic ones or those with severe&#xD;
      disease. The transmission potential of SARS CoV-2 is potentially greater than earlier viral&#xD;
      outbreaks of SARS-CoV and MERS-CoV.Routine measures of social distancing, personal hand&#xD;
      hygiene and limited outdoor contact activities have shown benefits to limit corona virus&#xD;
      infection. However, the role of vitamin D in SARS-CoV-2 infection is sparingly explored&#xD;
      despite the knowledge of an immunomodulatory role and protective effect of vitamin D against&#xD;
      viral infections. Meta-analysis of five clinical trials of vitamin D supplementation found&#xD;
      that those receiving vitamin D supplementation had fewer respiratory tract infections (odds&#xD;
      ratio = 0.58 (95%CI, 0.42 - 0.81).Any immune-modulatory effect of vitamin D is likely to be&#xD;
      observed at levels which are considered higher than that required for normal bone metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA)</measure>
    <time_frame>7 days</time_frame>
    <description>Sequential Organ Failure Assessment score at day 7. SOFA score range from 1 to a maximum of 24. A greator score suggests worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>3 days</time_frame>
    <description>Sequential Organ Failure Assessment score at day 3. SOFA score range from 1 to a maximum of 24. A greator score suggests worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>14 days</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) score at day 14. SOFA score range from 1 to a maximum of 24 score. A greator score suggests worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamn D 6 lakh IU oral stat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo equal volume/ weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol 6 lakh IU</intervention_name>
    <description>vitamin D levels and serum calcium will be assessed at day 3,7, 14.</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. RT-PCR proven SARS-CoV-2 infection or computed tomography scan findings compatible&#xD;
             with the COVID19 disease (bilateral multifocal ground-glass opacities â‰¥50%)&#xD;
&#xD;
          2. Moderate to severe COVID-19 defined by PFR ratio of &lt;200&#xD;
&#xD;
          3. SOFA score&gt;4&#xD;
&#xD;
          4. Patients with vitamin D deficiency defined as 25 (OH)D level&lt;20 ng/ml&#xD;
&#xD;
          5. Age&gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Vitamin D sufficient or already receiving vitamin D supplements 2. Active&#xD;
             malignancy 3. Hypercalcemia, hyperparathyroidism 4. Chronic kidney disease (eGFR&lt;30&#xD;
             ml/min) 5. Pregnant and lactating women 6. Patient on mechanical ventilation at ICU&#xD;
             admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deptt of Endocrinology</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ashu Rastogi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

